深圳翰宇药业股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300199 证券简称：翰宇药业 公告编号：2025-029 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于2025年 6月6日召开第六届董事会第五次会议审议通过了《关于拟续聘公司2025年度审计 机构的议案》，同意续聘立信会计师事务所（特殊普通合伙）（以下简称"立信"） 为公司2025年度审计机构，本议案将在年度内择机提交至公司股东大会审议，现 将有关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于 1927 年 在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会 计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立信是国际会计网 络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具有证券、期货业 务许可证，具有 H 股审计资格，并已向美国公众公司会计监督委员会（PCAOB） 注册登记。 截至 2024 ...

关于向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"）于 2025 年 6 月 6 日召开第 六届董事会第五次会议，审议通过了《关于向银行申请综合授信额度的议案》， 为支持公司业务快速发展与战略布局，进一步拓展多元化融资渠道、优化融资结 构，董事会同意公司向银行申请不超过 4 亿元人民币的综合授信额度，现将具体 情况公告如下： 证券代码：300199 证券简称：翰宇药业 公告编号：2025-028 深圳翰宇药业股份有限公司 以上综合授信事宜，董事会授权公司董事长或授权代表就相关文件签字或盖 章，授权经营层根据资金需求情况在前述授信额度内使用。 特此公告。 深圳翰宇药业股份有限公司董事会 2025年6月7日 1、同意公司向上海银行股份有限公司深圳分行申请额度不超过 2 亿元人民 币的综合授信额度，授信期限不超过 3 年。本次融资授信担保方式及授信额度与 期限以银行实际审批为准。 2、同意公司向广东华兴银行股份有限公司深圳分行申请额度不超过 2 亿元 人民币的综合授信额度，授信期限不超过 3 ...

一、董事会会议召开情况 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于 2025 年 6 月 4 日以电子邮件并电话通知方式向公司全体董事发出了关于召开第六届董事会 第五次会议的通知。 本次会议于 2025 年 6 月 6 日下午 15:30 在公司龙华总部 2006 董事会会议室 以现场结合通讯方式召开。会议应出席董事 9 人，实际出席会议董事 9 人，其中 董事唐洋明先生、独立董事胡文言先生、康志红女士以通讯表决方式出席会议。 本次会议由董事长曾少贵先生召集和主持，公司监事及高级管理人员列席了本次 会议。 证券代码：300199 证券简称：翰宇药业 公告编号：2025-027 深圳翰宇药业股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、备查文件 1、《深圳翰宇药业股份有限公司第六届董事会第五次会议决议》； 本次会议的召集、召开符合《中华人民共和国公司法》和《公司章程》的有 关规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于向银行申请综合授信额度的议案》； 具体内容详见公 ...

翰宇药业（300199）始终坚持"创仿结合"战略，围绕抗感染、代谢疾病等重大疾病领域构建了多层次创 新研发管线。如在GLP-1类药物方面，已形成"短期突破、中期储备、长期探索"的清晰布局。 GLP-1类药品方面，公司利拉鲁肽注射液已于2024年12月23日获美国FDA首仿批准上市，目前已累计向 美国发出近180万支制剂。同时，公司与合作伙伴在全球30多个国家和地区陆续开展注册申报，预计相 关药品有望在未来1—2年内陆续获得海外市场准入。 公司司美格鲁肽注射液降糖及减重两个适应症的三期临床均完成了受试者入组，目前正在随访中，其中 减重适应症与三生蔓迪达成对外授权合作，就中国、巴西、埃及、墨西哥、欧亚联盟区域、海合会成员 国、北非等市场开展布局，预计2026年中国及美国申报上市。公司也已经开展司美格鲁肽片剂的研发工 作，未来将与注射剂形成互补。 2025年第一季度，公司实现营业收入3.1亿元，同比增长106.29%；归母净利润6986.84万元，同比扭亏 为盈，核心业务GLP-1类药物的国际化放量成为增长主引擎。在此基础上，公司仍长期保持高强度研发 投入，为管线深度布局提供坚实保障。 未来，公司将继续以多肽药物为 ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 1、2025年4月24日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰 宇药业"）第六届董事会第三次会议审议通过《关于提请召开2024年年度股东 大 会 的 议 案 》 ， 详 见 公 司 在 中 国 证 监 会 指 定 信 息 披 露 网 站 （http://www.cninfo.com.cn）披露的相关公告。 证券代码：300199 证券简称：翰宇药业 公告编号：2025-026 2024年年度股东大会召开的基本情况如下： 深圳翰宇药业股份有限公司 2024年年度股东大会决议公告 会议召集人：公司董事会 会议方式：本次会议采取现场投票和网络投票相结合的方式 会议召开时间：2025年5月20日（周二）下午15:30 会议地点：深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼会 议室 会议主持人：董事长曾少贵先生 本次会议的召集、召开符合《公司法》《上市公司股东会规则》以及《公 ...

关于 深圳翰宇药业股份有限公司 二〇二四年度股东大会 的 法律意见书 法律意见书 国浩律师（深圳）事务所 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙 ·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨 Hongkong·Paris·Madrid·Silicon Valley·Stockholm·New York·Malaysia·Cambodia 深圳市深南大道 6008 ...

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical sector, indicating a positive outlook for investment opportunities in this industry [2]. Core Insights - The pharmaceutical sector has shown resilience with a weekly increase of 1.27%, outperforming the CSI 300 index by 0.16 percentage points, ranking 11th among 31 sectors [7][26]. - The report highlights the potential recovery of the industry due to favorable policies and the gradual rebound of the hospital market, which was previously impacted by anti-corruption measures and centralized procurement [4][26]. - The focus on innovative therapies is expected to drive significant growth, with an emphasis on domestic BIC/FIC innovative drugs showing steady improvement in both quantity and quality [4][26]. Summary by Sections 1. Pharmaceutical Sector Performance - The pharmaceutical sector's weekly performance was +1.27%, with sub-sectors such as Traditional Chinese Medicine II (+1.73%), Medical Services (+1.45%), and Chemical Pharmaceuticals (+1.44%) showing notable gains [7][26]. 2. Key Company Ratings - Companies such as Aosaikang (002755.SZ) and Cloudtop New Medicine (01952.HK) received "Buy" ratings, while Renfu Pharmaceutical (600079.SH) and Dize Pharmaceutical (688192.SH) were rated as "Hold" [1][4]. 3. Notable Industry News - BeiGene initiated a head-to-head Phase III clinical trial for BGB-16673, a targeted BTK PROTAC drug, which has shown promising results in earlier trials [26][27]. - AbbVie received FDA approval for its c-Met targeted ADC drug, marking a significant milestone in the ADC product line [29][30]. 4. Investment Recommendations - The report recommends focusing on high-quality targets within the formulation sector, particularly companies with efficient management and strong product pipelines, such as Aosaikang and Dize Pharmaceutical [4][26].

Core Viewpoint - The collaboration between Hanyu Pharmaceutical and Shenzhen Carbon Cloud Smart Peptide Technology Co., Ltd. aims to develop a novel peptide drug targeting GLP-1R/GIPR/GCGR for metabolic disease treatment, particularly for weight control [2][3]. Group 1: Collaboration Details - Hanyu Pharmaceutical will handle preclinical research, IND application, clinical trials, and product registration, covering associated costs [3]. - Carbon Cloud Smart Peptide will be responsible for molecular screening and will bear all development costs during this process [3]. - Hanyu Pharmaceutical will pay up to 38 million yuan in milestone payments to Carbon Cloud Smart Peptide and will share revenue based on sales, with a maximum of 10% for North America and 3% for other global regions [3]. Group 2: Market Position and Product Development - Hanyu Pharmaceutical has established a strong position in the GLP-1 market, particularly with its experience in the development of liraglutide and other peptide products [4]. - The collaboration marks Hanyu Pharmaceutical's entry into the innovative research frontier of weight loss drugs, enhancing its global standing in the GLP-1 sector [4]. - The new drug is expected to show significant weight loss effects in preclinical studies, outperforming existing treatments like terzepatide in specific metrics [5][6].

Group 1 - Shengyi Electronics plans to repurchase shares with a total amount between 50 million and 100 million yuan, at a price not exceeding 43.02 yuan per share, for employee stock ownership plans [1] - Guoyao Modern's subsidiary has passed the consistency evaluation for the quality and efficacy of a generic drug, which is used for treating severe infections [1] - Tianhe Magnetic Materials' subsidiaries have obtained project filing notices for high-performance rare earth permanent magnet projects, with total investments of 100 million yuan and 50 million yuan respectively [1][2] Group 2 - Dream Lily intends to repurchase shares with an amount between 85 million and 170 million yuan, at a price not exceeding 10.90 yuan per share, supported by a loan commitment of up to 150 million yuan [3] - Weifu High-Tech has received a loan commitment of up to 135 million yuan from a financial institution for share repurchase [3] Group 3 - Lu'an Environmental Energy reported a coal sales volume of 4.51 million tons in April, a year-on-year increase of 17.75% [5] - *ST Tianshan reported a significant decline in livestock sales and revenue, with a revenue of 70,500 yuan in April, down 95.68% year-on-year [7] Group 4 - Feirongda announced a cash dividend of 0.38 yuan per 10 shares, with a total distribution of 21.9 million yuan [8] - Zhejiang Rongtai's shareholders and executives plan to reduce their holdings by up to 1.93% of the company's shares [9] Group 5 - Changhua Group's subsidiary won the land use rights for an industrial site in Ningbo for 27.05 million yuan, intended for manufacturing and related business [11] - Zejing Pharmaceutical's new drug application for a treatment for severe alopecia has been accepted by the regulatory authority [13][14] Group 6 - Hainan Mining plans to distribute a cash dividend of 0.8 yuan per 10 shares, totaling 1.59 billion yuan [15] - China Jushi plans to distribute a cash dividend of 0.24 yuan per share, totaling 9.61 billion yuan [16] Group 7 - Zhengzhong Design's subsidiary has obtained a utility model patent for an acrylic signage guide [18] - Rundu Co., Ltd. received approval for a veterinary drug product, which is intended for treating bacterial diseases in livestock [20] Group 8 - Emei Mountain A announced the resignation of its general manager due to work reasons [22] - Tonghua Dongbao's insulin injection has received a registration certificate in Nicaragua, allowing for sales in that market [23] Group 9 - Dizu Fashion's subsidiary has completed the registration of a private equity investment fund [24] - Ningbo Gaofa plans to increase capital by 60 million yuan in its subsidiary for operational needs [26] Group 10 - Haichuan Intelligent has obtained two utility model patents for material handling devices [27] - Newland's subsidiary signed a deep cooperation agreement with Alibaba Cloud for AI model applications [29] Group 11 - Rui Neng Technology's controlling shareholder plans to reduce its stake by up to 2.89% [30] - Guomai Culture intends to repurchase shares between 50 million and 100 million yuan for capital reduction [31] Group 12 - Shaanxi Construction won major construction projects totaling 7.88 billion yuan in April [32] - Hanyu Pharmaceutical signed a joint development agreement for a new peptide drug with a partner [34] Group 13 - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a stock suspension [35] - Haizheng Pharmaceutical plans to repurchase shares between 50 million and 100 million yuan for employee stock ownership [36] Group 14 - Tianqiao Hoisting's controlling shareholder plans to increase its stake by 75 million to 150 million yuan [37] - Tiandi Online's controlling shareholder is transferring shares to introduce a strategic investor [38] Group 15 - Hongchang Technology plans to invest 15 million yuan in a joint venture with a partner [39] - Rabbit Baby's subsidiary is preparing for an IPO in Hong Kong [41] Group 16 - Wol Nuclear Materials is planning to issue H-shares for listing in Hong Kong [42] - Tangyuan Electric plans to raise up to 864 million yuan through a private placement for various projects [43] Group 17 - Tongrun Equipment's major shareholders plan to reduce their holdings by up to 2% [44] - Linzhou Heavy Machinery plans to raise up to 600 million yuan through a private placement [46] Group 18 - China Merchants Securities announced the resignation of its vice president [47] - Shangsheng Electronics plans to issue convertible bonds to raise up to 330 million yuan for various projects [48] Group 19 - Longda Co., Ltd.'s major shareholder plans to reduce its stake by up to 1% [49] - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [50] Group 20 - Silek has signed a strategic cooperation agreement with a battery manufacturer [51] - Boyun New Materials' major shareholder plans to reduce its stake by up to 3% [53]

5月12日晚间，多肽药物领军企业翰宇药业（300199）（300199.SZ）发布公告称，公司与深圳碳云智肽 药物科技有限公司签署了《GLP-1R/GIPR/GCGR 三重激动剂多肽创新药物联合开发协议》，双方将共 同开发应用于体重控制等代谢性疾病治疗领域的多肽创新药物。 根据协议，翰宇药业将负责临床前研究、IND 申报、临床试验及产品注册申报，并承担相应费用。碳 云智肽则负责分子筛选工作，并承担筛选过程中的所有开发费用。此外，翰宇药业将按照项目重要节点 向碳云智肽支付最高合计3800万元的里程碑付款。未来产品获批上市销售后，翰宇药业将根据销售收入 情况，向碳云智肽支付不超过10%（北美区域）或3%（全球其他区域）的收益分成。 对于此次合作，翰宇药业表示将有助于提升公司在代谢类疾病治疗方向的创新能力和产品多样性，为公 司未来在健康医疗领域的长远发展奠定坚实基础。 联合开发三靶点"减肥药" 临床前数据出色 作为GLP-1原料药出海先锋及利拉鲁肽注射液FDA首仿企业，在利拉鲁肽等成熟的多肽产品领域，翰宇 药业已建立稳固的行业地位。围绕优势领域进一步深耕，此次公司与碳云智肽合作成功开发出三重激动 剂多肽新药，则有望 ...